OPKO Health Inc (NAS:OPK)
$ 1.73 0.14 (8.81%) Market Cap: 1.07 Bil Enterprise Value: 1.18 Bil PE Ratio: 0 PB Ratio: 0.77 GF Score: 45/100

OPKO Health Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 11:45PM GMT
Release Date Price: $1.01 (-2.88%)
Sun Shubitha JPMorgan

Welcome, everyone. I'm [Sun Shubitha] with JP Morgan Healthcare. And we are pleased to have with us Dr. Elias Zerhouni, President and Vice Chairman of OPKO Health. For logistic purposes, please reserve any questions you may have after the end of this presentation.

Elias Zerhouni OPKO Health
Inc. - President & Vice Chairman

Well, thank you very much, very much, and thank you all for attending.

Last year, we presented the fact that OPKO had acquired a company called ModeX Therapeutics, of which I was a co-founder. And since then, we've achieved quite a bit of milestones across the company. A very important milestone occurred in 2023, which really announced a transformation, something that we've been strategizing to make happen over the previous years. Because one of the major milestone that was met this year was in fact, the approval of our long-acting growth hormone product, somatrogon, known as NGENLA, which was approved by the FDA in June and is one of the leading long-acting growth hormone product in the world, partner with Pfizer.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot